Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$0.52 - $0.98 $72 - $137
140 New
140 $0
Q1 2023

May 12, 2023

SELL
$0.91 - $1.85 $5,346 - $10,868
-5,875 Reduced 87.46%
842 $0
Q4 2022

Feb 08, 2023

SELL
$0.69 - $328.8 $5,768 - $2.75 Million
-8,360 Reduced 55.45%
6,717 $6,000
Q3 2022

Nov 10, 2022

BUY
$0.26 - $420.0 $3,920 - $6.33 Million
15,077 New
15,077 $16,000
Q1 2022

May 16, 2022

SELL
$278.4 - $698.4 $1.31 Million - $3.29 Million
-4,716 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$556.8 - $1068.0 $2.63 Million - $5.04 Million
4,716 New
4,716 $13,000

About Cingulate Inc.


  • Ticker CING
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,309,400
  • Market Cap $58.6M
  • Description
  • Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...
More about CING
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.